Education
About Us
Working with TipRanks
Follow Us
Bluebird bio Inc (GB:0HOH)
:0HOH
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 0.00%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong patient start growth, successful cost reduction efforts, and promising reimbursement pathways. However, these positives were countered by a decrease in quarterly revenue, cash resource challenges, and pending shareholder approvals, creating a balanced outlook.Company Guidance
During bluebird bio's third-quarter 2024 earnings call, the company provided optimistic guidance, highlighting a doubling of patient starts from 27 to 57 since the previous quarter and a total of 74 starts for the year. They emphasized plans to reduce cash operating expenses by 20% starting in Q3 2025, paving the way for financial stability and cash flow breakeven in the second half of the year. The company reported $10.6 million in Q3 revenue, down from $16.1 million in Q2, but projected a rebound to at least $25 million in Q4. Manufacturing capacity is deemed sufficient to meet the goal of 40 drug product deliveries per quarter by late 2025, supported by a robust Qualified Treatment Center (QTC) network. As of September 30, 2024, bluebird bio held $118.7 million in cash, including $48 million in restricted cash, and is focusing on extending its runway through additional financing and cost-saving initiatives.Significant Increase in Patient Starts
Patient starts have more than doubled from 27 to 57 since Q2 2024, with 74 patient starts completed or scheduled for 2024 and 30 more scheduled for 2025.
Successful Reduction in Cash Operating Expenses
Implemented steps to reduce cash operating expenses by 20% in Q3 2025.
Strong Manufacturing Capacity and Future Expansion Plans
Current manufacturing capacity is adequate to meet projections with plans to double LYFGENIA capacity in 2026.
Encouraging Reimbursement and Access Pathways
Over half of U.S. states have affirmed coverage for LYFGENIA, and no ultimate denials have been recorded across Medicaid and commercial payers.
---
GB:0HOH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0HOH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $3.90 | $3.90 | 0.00% |
Feb 25, 2025 | $8.04 | $8.04 | 0.00% |
Nov 14, 2024 | $7.66 | $7.73 | +0.84% |
Aug 14, 2024 | $20.80 | $16.47 | -20.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Bluebird bio Inc (GB:0HOH) report earnings?
Bluebird bio Inc (GB:0HOH) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Bluebird bio Inc (GB:0HOH) earnings time?
Bluebird bio Inc (GB:0HOH) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Bluebird bio Inc stock?
The P/E ratio of Bluebird Bio is N/A.
What is GB:0HOH EPS forecast?
Currently, no data Available
---
